临床病理学特征和预后三阴性无癌:一个病例对照研究
Chiho Suzuki1,2, Akimitsu Yamada1,3, Kei Kawashima4
1Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa 236-0004, Japan.
World journal of oncology
|November 29, 2023
概括
雄激素受体阳性无细胞癌 (AC),一种罕见的乳腺癌,预后良好. 即使是具有AR阳性的三重阴性AC患者也不需要辅助化疗,并且没有复发.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 胰腺癌 (AC) 是日本罕见的乳腺癌亚型,占所有病例的1%.
- 临床病理学特征和AC的预后因素,特别是雄激素受体 (AR) 的作用,尚不清楚.
研究的目的:
- 评估AC的临床病理学特征.
- 根据AR表达的存在或不存在来评估AC的预后.
主要方法:
- 一项回顾性多中心病例控制研究 (YCOG1701研究) 涉及53名在2000年至2017年期间在日本诊断的AC患者.
- 患者被分为三重阴性纯AC (TN-PAC;AR阳性) 和其他AC类型 (其他AC;ER阳性和/或HER2阳性或AR阴性).
主要成果:
- 与其他AC相比,TN-PAC (AR阳性) 病例与较小的瘤大小 (1.4比2.1厘米) 和较少的结节转移 (12.5%比37.9%) 有关.
- 在TN-PAC组中没有观察到复发,而在另一个AC组中出现了5例复发,尽管术后辅助化疗的发病率相似.
结论:
- 包括三阴性亚型在内的AR阳性AC显示出良好的预后,可能消除了辅助化疗的需要.
- 需要进行进一步的临床试验,研究AR阳性AC的治疗降级策略.
更多相关视频
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
1.3K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.5K
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Survival Analysis
356
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
356
